Table 2.

Effect of finerenone in clinical treatment

Type	Object	Follow-up period	Effect of outcome
Clinical trial (FIDELIO-DKD)	5674 patients with type 2 diabetes with CKD	Median follow-up of 2.6 years	Reduce risks of CKD progression and cardiovascular events [73]
Clinical trial (FIGARO-DKD)	7352 patients with CKD and type 2 diabetes	Median follow-up of 3.4 years	Improve cardiovascular outcomes [74]
Randomized, double-blind trial (ARTS Part B)	392 patients with HFrEF and moderate CKD	29 ± 2 days	Decrease the levels of B-type natriuretic peptide, amino-terminal proBNP, and albuminuria; have lower incidences of hyperkalaemia and worsening renal function than spironolactone [75]
Randomized, double-blind trial (ARTS-HF)	1066 patients with worsening chronic heart failure and diabetes mellitus and/or CKD	90 days	Induce a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone [77]
Meta-analysis	51,496 patients with type 2 diabetes and CKD	Ranged from 90 days to 4 years	Reduce the risk of major adverse cardiovascular events, renal outcome and hospitalization for heart failure [78]